Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Maze Therapeutics, Inc.NASDAQ: MAZE
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $12.41M rose 58.6% year over year, ahead of the +38.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 18.3% from the prior quarter. Over 3 fiscal years it compounded at +14.7% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 10 analysts of $15.79M (-54.2%) for the fiscal year ending Dec 2026, a slowdown from the +30.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $12.41M+18.3% QoQ
- Last fiscal yearDec 2025
- $34.45M+30.4% YoY
- LTMMar 2026
- $39.04M+38.9% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 34.45M USD
- Year-over-year change
- +30.4%
- 3-year CAGR
- +14.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 34.45M | +30.4% |
| FY2024 | 2024-12-31 | 26.42M | +7.4% |
| FY2023 | 2023-12-31 | 24.61M | +7.8% |
| FY2022 | 2022-12-31 | 22.83M | — |
Selling, General & Admin vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +38.9% is the 2nd highest of 8, against a peer median of +23.4%.
- Selling, general & admin amounts to 195.2% of revenue for MAZE, versus a peer median of 70.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $376.47M USD | +23.4% | +19.5% | 57.8% | |
| LTM Mar 2026 | $356.28M USD | +23.3% | +63.9% | 83.3% | |
| LTM Jun 2026 | $351.33M USD | +8.3% | +2.1% | 34.8% | |
| FY2025 | €53.89M EUR | +215.2% | +51.5% | 1202.1% | |
| LTM Mar 2026 | $39.04M USD | +38.9% | +14.7% | 195.2% | |
SEPNSepterna, Inc. | LTM Sep 2026 | $36.57M USD | +38.0% | — | 38.0% |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $28.7M USD | +27.8% | +43.3% | 278.2% |
| LTM Mar 2026 | $9.79M USD | +21.7% | +16.7% | — | |
| Peer median (excluding MAZE) | — | +23.4% | +31.4% | 70.6% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 167.5M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 2.4M |
| Gross Profit | 0 | 0 | 167.5M | (2.4M) |
| Gross Margin | — | — | 100.0% | — |
| Research & Development | 88.19M | 73.95M | 83.5M | 108.45M |
| Selling, General & Admin | 22.83M | 24.61M | 26.42M | 34.45M |
| Operating Expenses | 111.03M | 98.55M | 109.91M | 140.5M |
| Depreciation & Amortization | 3.82M | 4.09M | 3.3M | 2.4M |
| EBITDA | (111.12M) | (96.33M) | 56.7M | (128.72M) |
| EBITDA Margin | — | — | 33.9% | — |
| Operating Income | (111.03M) | (98.55M) | 57.59M | (142.9M) |
| Operating Margin | — | — | 34.4% | — |
| Interest Income | 2.03M | 1.97M | 4.65M | 11.78M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (3.91M) | (1.86M) | (4.18M) | 11.78M |
| Income Before Tax | (114.94M) | (100.42M) | 53.4M | (131.12M) |
| Pre-Tax Margin | — | — | 31.9% | — |
| Income Tax Expense | 0 | 0 | 1.17M | 0 |
| Net Income | (114.94M) | (100.42M) | 52.23M | (131.12M) |
| Net Margin | — | — | 31.2% | — |
| EPS (Basic) | (2.63) | (2.29) | 0.08 | (3.05) |
| EPS (Diluted) | (2.63) | (2.29) | 0.08 | (3.05) |
| Weighted Avg Shares | 43.78M | 43.78M | 43.8M | 42.98M |
| Weighted Avg Shares (Diluted) | 43.78M | 43.78M | 43.8M | 42.98M |
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.